PARSIPPANY, N.J.– YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that they are now the exclusive supplier of the authorized generic levothyroxine sodium capsules in the United States. Levothyroxine Sodium Capsules are used to treat hypothyroidism.
“When it comes to managing hypothyroidism, not all levothyroxine medications are created equal,” said Stephen Beckman, CEO of YARAL Pharma. “Each year, millions of patients are treated with levothyroxine. For those who have trouble tolerating traditional levothyroxine tablets, the answer may lie in the dosage form. YARAL is pleased to offer patients a high-quality gel capsule product, specially formulated to improve the tolerability of LT4 therapy, supported by continuity of supply, and an exceptional level of customer service.”
YARAL Pharma’s Levothyroxine Sodium Capsules, a unique gel-cap formulation designed to address concerns of absorption and tolerability commonly found in levothyroxine tablets are available in twelve dosage strengths. The capsules contain only four simple ingredients: levothyroxine, gelatin, glycerin and water, and are free from sugars, dyes, alcohol, wheat starch (gluten), and lactose. This is especially important for patients with hypothyroidism who have allergies or sensitivities to ingredients commonly found in levothyroxine tablets or for those with certain gastrointestinal conditions.
